Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

This treatment has been approved for sale to the public.
Sponsor:
Collaborator:
Multiple Myeloma Research Foundation
Information provided by (Responsible Party):
Onyx Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01410500
First received: August 2, 2011
Last updated: May 1, 2015
Last verified: May 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This treatment has been approved for sale to the public.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given